- Home
- CVKD vs CLPS Comparison
CVKD vs CLPS Comparison
Compare CVKD & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- CLPS
- Stock Information
- Founded
- CVKD 2022
- CLPS 2005
- Country
- CVKD United States
- CLPS Hong Kong
- Employees
- CVKD N/A
- CLPS N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- CLPS Computer Software: Prepackaged Software
- Sector
- CVKD Health Care
- CLPS Technology
- Exchange
- CVKD Nasdaq
- CLPS Nasdaq
- Market Cap
- CVKD 29.5M
- CLPS 26.0M
- IPO Year
- CVKD 2023
- CLPS 2018
- Fundamental
- Price
- CVKD $12.71
- CLPS $0.97
- Analyst Decision
- CVKD Strong Buy
- CLPS
- Analyst Count
- CVKD 1
- CLPS 0
- Target Price
- CVKD $32.00
- CLPS N/A
- AVG Volume (30 Days)
- CVKD 35.8K
- CLPS 11.8K
- Earning Date
- CVKD 08-06-2025
- CLPS 03-05-2025
- Dividend Yield
- CVKD N/A
- CLPS 13.35%
- EPS Growth
- CVKD N/A
- CLPS N/A
- EPS
- CVKD N/A
- CLPS N/A
- Revenue
- CVKD N/A
- CLPS $153,816,045.00
- Revenue This Year
- CVKD N/A
- CLPS N/A
- Revenue Next Year
- CVKD N/A
- CLPS N/A
- P/E Ratio
- CVKD N/A
- CLPS N/A
- Revenue Growth
- CVKD N/A
- CLPS 5.81
- 52 Week Low
- CVKD $5.70
- CLPS $0.68
- 52 Week High
- CVKD $22.90
- CLPS $1.70
- Technical
- Relative Strength Index (RSI)
- CVKD 49.98
- CLPS 45.57
- Support Level
- CVKD $11.00
- CLPS $0.90
- Resistance Level
- CVKD $13.56
- CLPS $0.94
- Average True Range (ATR)
- CVKD 1.15
- CLPS 0.04
- MACD
- CVKD 0.25
- CLPS -0.00
- Stochastic Oscillator
- CVKD 80.97
- CLPS 38.46
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.